Two people can have similar health needs and very different routes to treatment. One has a workplace health plan that helps pay for care. The other must navigate exclusions, compare private options or decide whether another recurring expense will fit into an already stretched budget.
In the United States, the debate over employer coverage of GLP-1 weight-loss medications brings this divide into focus. For employers, it raises difficult questions about benefits budgets. For patients, the question is more immediate: can they access appropriate care and keep paying for it?
A socially sustainable healthcare system needs to consider both perspectives. Financial viability matters, but so does the distribution of costs, access and risk.
Key takeaways
- US employer coverage of GLP-1 medications for weight loss varies substantially by company size.
- Having health insurance does not necessarily mean a particular treatment is covered or affordable.
- Direct-to-consumer services offer another route to care, but access and insurance coverage are separate questions.
- Compounded medications are not FDA-approved and should not be presented as equivalent to approved products.
- Fairer healthcare benefits should consider continuity, clear eligibility rules and patients’ ability to manage ongoing costs.
Access to treatment is not the same as coverage
People seeking care outside their workplace health plan may encounter direct-to-consumer services such as the TrimRx program, which describes itself as a telehealth weight-loss service connecting patients with medical providers. Its website also describes access to compounded medications. This illustrates a separate route to seeking treatment; it does not establish that an employer pays for the service, that insurance reimburses it or that a particular medication is appropriate for an individual.
That distinction matters. Making a service available answers a different question from making it financially accessible. A worker who can arrange a consultation but cannot sustain the treatment costs still faces a substantial barrier.
The medication itself also matters. The US Food and Drug Administration explains that compounded drugs are not FDA-approved and do not undergo its review for safety, effectiveness and quality before marketing. It recommends using compounded drugs only when a patient’s medical needs cannot be met by an FDA-approved drug. A prescription and an online consultation do not erase this distinction.
The employer coverage divide
The 2025 KFF Employer Health Benefits Survey shows how uneven coverage can be. Among employers offering health benefits, GLP-1 coverage primarily for weight loss in their largest health plan was reported by:
- 16% of firms with 200 to 999 workers.
- 30% of firms with 1,000 to 4,999 workers.
- 43% of firms with at least 5,000 workers.
These are percentages of firms in specified size groups, not percentages of all American workers. They also describe coverage for weight loss, rather than every medical use of these medications.
The figures nevertheless reveal an important disparity. Working for a larger organisation can mean a different benefits landscape. An employee’s clinical needs do not change simply because their workplace is smaller, yet their route to financial support may look very different.
Insurance does not guarantee affordability
Coverage is only part of the story. In a KFF poll conducted in October and November 2025, 56% of adults who had used GLP-1 medications said they were difficult to afford. The poll covered use for weight loss, diabetes and other conditions, so this figure should not be treated as specific to employer-funded obesity care.
This is the broader problem explored in Unsustainable’s examination of why US healthcare costs are unsustainable for patients: the existence of an insurance policy can coexist with considerable financial pressure.
Consider two hypothetical workers asked to pay the same monthly amount. For one, it is manageable. For the other, it competes with rent, food or childcare. An identical payment requirement can produce unequal practical access.
A meaningful assessment of a benefit therefore needs to ask what patients actually pay over time, rather than stopping at whether a treatment appears somewhere in the plan.
Employers face real costs, but savings are not automatic
A Peterson-KFF Health System Tracker analysis combines survey findings with employer discussions held in 2025. It describes concerns about higher-than-expected use and prescription spending, alongside changes to eligibility and support requirements. Employers differed in their expectations about whether treatment would reduce other healthcare costs or deliver a return on investment.
Those concerns deserve scrutiny rather than dismissal. A benefits programme has to remain financially workable. Equally, an employer should not assume that moving a bill outside its health plan makes the underlying need disappear.
From a patient’s perspective, a policy that reduces employer spending by increasing personal costs may simply redistribute the burden. The fair question is where the cost goes and whether the person receiving it can cope.
Care needs to survive changes in employment
Another test is what happens when a worker leaves a job or loses eligibility for its health plan. The US Department of Labor describes COBRA as a mechanism that can allow eligible workers and families to continue group health coverage temporarily after specified events, including job loss or reduced working hours. It is subject to conditions and does not apply universally.
The existence of a continuation mechanism does not settle every patient’s treatment needs. Benefits design should account for transitions, including clear information about coverage ending, available options and how patients can discuss ongoing care with their clinicians.
A healthcare system should not measure success solely at the moment treatment begins. Whether appropriate care remains accessible through a change in circumstances is an equally important question.
What fairer benefits could look like
The World Health Organization’s report on health equity places health inequalities within the wider distribution of resources and opportunities, including housing, education and employment. The employer-treatment divide is one practical setting in which to examine that broader issue.
For employers, a fairer approach would make eligibility rules understandable, provide clear explanations of decisions and consider how required appointments or support programmes fit around workers’ lives. Patient information should distinguish approved medicines from compounded products and explain ongoing costs without relying on an introductory price.
Workers should also be able to seek information without unnecessary disclosure of personal medical details to their managers. Benefits communication can explain available support while leaving individual treatment decisions to patients and qualified clinicians.
These priorities align with patient-centred sustainable healthcare: assess a system by how it serves people throughout their care, including those who find it hardest to navigate.
The weight-loss treatment debate asks a wider question about healthcare’s social foundations. Who receives support, who carries the cost and what happens when their circumstances change? Employer benefits can help answer those questions more fairly, provided their design looks beyond access on paper to access people can actually sustain.